Antibody Drug Discovery Market Research Report Information By Type (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, and Intracellular Antibodies), By Technique (Hybridoma, Phage Display, and Others), By Application (Oncology, Cardiology, Infectious Diseases, Autoimmune Diseases, and Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutes), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Global Antibody Drug Discovery Market Overview

Antibody Drug Discovery Market size was valued at USD 5.70 billion in 2022. The Antibody Drug Discovery Market industry is projected to grow from USD 6.21 billion in 2023 to USD 13.37 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2032).

Rising incidences of infectious diseases worldwide and a greater inclination towards personalized medicine to avoid adverse effects are propelling the growth of the market.  

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antibody Drug Discovery Market Trends

• Increasing incidences of infectious diseases

The growth of the antibody drug discovery market has been driven by increasing demand for antibodies to treat infectious diseases, including meningococcal meningitis, pneumococcal pneumonia, and streptococcal infection. The antibody drugs neutralize the virus or bacteria, preventing it from infecting cells, activating the immune system to attack the virus or bacteria, and blocking the spread of the virus or bacteria in the body. 

In April 2023, the World Health Organization reported that bacterial meningitis is a concern across the globe owing to increasing incidences. Around 1 in 6 people worldwide die from meningitis, and 1 in 5 have severe complications. Moreover, antibody drug discovery is growing at a rapid pace owing to an increase in hepatitis diseases across the globe. The World Health Organization reported that 296 million people suffered from Hepatitis B, 58 million from Hepatitis C, and 1.5 million from both chronic hepatitis B and C in 2019.

Moreover, an emerging method of disease treatment and prevention called Precision Medicine (PM) primarily considers a person's unique gene variability in addition to environmental factors and lifestyle choices. The most recent generation of medications that best fit the PM paradigm are monoclonal antibodies (mABs). Its first paradigmatic is targeted therapy in oncology; thus, growing incidences of cancer across the globe will create lucrative growth opportunities for the market during the forecast period. According to the Global Cancer Observatory, there were 19.5 million new cases of cancer across the globe in 2020, and it has been estimated that this number will increase to 30.2 million by 2040.

Therefore, rising demand for emerging infectious diseases and the growing preference for personalized medicine are boosting the growth of the market.

Antibody Drug Discovery Segment Insights

Antibody Drug Discovery Type Insights

The Antibody Drug Discovery Market is segmented, based on type, into monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and intracellular antibodies. The monoclonal antibodies segment held the majority share of the market, with a market share of approximately 40–55% in 2022, and is the fastest-growing segment during the forecast year. Monoclonal antibodies work as a targeted drug therapy that recognizes and finds specific proteins in cancer cells. 

Moreover, antibody drug discovery has been influenced by the various properties of monoclonal antibodies, such as their ability to treat cancer, organ transplants, inflammatory and autoimmune diseases, and nervous system disorders. Thus, increasing incidences of these above-mentioned diseases fuel the antibody drug discovery market. According to the National Multiple Sclerosis Society, approximately one million people was living with multiple sclerosis in the US until May 2023.

Thus, a wide range of properties to treat various diseases is fueling the monoclonal antibody segment's growth.

Antibody Drug Discovery Technique Insights

The Antibody Drug Discovery Market segmentation, based on technique, includes hybridoma, phage display, and others. The other segment includes transgenic mouse and single B cell technique. The hybridoma segment dominated the market in the base year, i.e., 2022, and is the fastest-growing segment during the forecast period, 2023–2032. This is due to the wide range of applications of hybridoma in antibody drug discovery, such as the fact that it generates monoclonal antibodies that are specific to a particular target molecule. 

Moreover, another application of hybridoma is screening antibody libraries, which identify antibodies for specific diseases that have the desired properties and can be engineered to be more specific, more potent, or more stable. Therefore, the broad range of applications of the hybridoma technique in antibody drug discovery to accelerate the antibody drug development process results in propelling segment growth.

FIGURE 2: ANTIBODY DRUG DISCOVERY MARKET, BY TECHNIQUE, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Antibody Drug Discovery Application Insights

On the basis of application, the Antibody Drug Discovery Market has been segmented into oncology, cardiology, infectious diseases, autoimmune diseases, and others. The other application segment includes ophthalmology and neurology. The oncology segment held the largest market share in 2022 and is the fastest-growing segment during the forecast period. This is owing to the increasing incidences of cancer across the globe, which is increasing the demand for personalized antibody medicine. 

Moreover, the cardiology and infectious disease segments show significant growth during the forecast period owing to a surge in infectious and cardiology diseases prevalence. According to the World Heart Federation, deaths from cardiovascular disease have surged by up to 60% globally from 1990 to 2021. Hence, the increasing demand for personalized medicine and the increasing incidences of the above-mentioned diseases are burgeoning the growth of the application segment.

Antibody Drug Discovery End User Insights

Based on end user, the Antibody Drug Discovery Market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, and academic & research institutes. The pharmaceutical and biotechnology companies segment dominated the market in the base year, i.e., 2022, and the contract research organizations segment is the fastest-growing segment during the forecast period, 2023–2032. Furthermore, the factors influencing the growth of the pharmaceutical and biotechnology companies’ segment are rising incidences of chronic diseases, growing demand for personalized medicine, and technological advancements. 

Antibody drug discovery technology development continues to diversify, resulting in a rich pipeline of new and innovative therapeutics. Moreover, the major players, Biocytogen Pharmaceuticals Co., Ltd. (China), Genscript Biotech Corporation (US), and Sartorius AG (Germany), are implementing antibody drug discovery technology to accelerate the development of antibody therapeutics driving the growth of the end user segment.

Antibody Drug Discovery Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. In North America, the antibody drug discovery market held the largest market share in 2022 due to the presence of major players in the US such as Charles River Laboratories (US), Creative Biolabs (US), and Twist Bioscience (US). In addition, the rising incidences of autoimmune diseases, including rheumatoid arthritis, is fueling the North America region’s growth. 

As per the Centers for Disease Control and Prevention, approximately 1 in 3 US adults suffered from arthritis (gout, fibromyalgia, lupus, rheumatoid arthritis, and osteoarthritis), which is approximately 19 million until 2023. Hence, the presence of major players in the region and increasing incidences of autoimmune diseases are fostering the growth of the North American antibody drug discovery market. Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: ANTIBODY DRUG DISCOVERY MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

The European antibody drug discovery market accounted for the second-largest market share due to favorable government support. The European government is encouraging the production of more animal-derived antibody drugs. In December 2020, the European Federation of Pharmaceutical Industries and Associations and the European Animal Research Association (EARA) set a vision to enhance the understanding and recognition of research involving animals across Europe. 

Moreover, it has been reported that animal-derived antibodies have been highly successful in drug discovery and therapeutics, with 90% of approved therapeutic antibodies in the last five years being animal-derived. Furthermore, the Germany antibody drug discovery market held the largest market in 2022, and the UK antibody drug discovery market is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific antibody drug discovery market is the fastest growing region from 2023 to 2032, owing to the growing incidence of cancer and the rising geriatric population in the region. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Furthermore, strategic formation in order to meet the demand of customers boosts the region’s growth. 

For instance, in June 2023, Sanyou (China) launched a novel antibody discovery platform that can generate hundreds of lead antibodies with good drug developability and provide a feasible solution to obtain bispecific antibodies.  Moreover, the China antibody drug discovery market accounted for the largest market share in 2022, and the India antibody drug discovery market is projected to be the fastest-growing market in the Asia-Pacific region.

Antibody Drug Discovery Key Market Players & Competitive Insights

Major market players are investing heavily in R&D in order to expand their service offering, which helps in driving the antibody drug discovery market growth. Market participants are also expanding their global footprint through various strategic initiatives such as new services platform lunch, contractual agreements, mergers & acquisitions, investments, and collaboration with other market players.

Charles River Laboratories (US) provides clinical testing and drug development services for vaccines, biosimilars, and medicines to treat several chronic diseases such as cardiovascular, skeletal, endocrine, central nervous system, cancer, and other diseases. The company operates through three segments, namely, Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (MS). Furthermore, in December 2019, Charles River Laboratories (US) provided access to Cosmic antibody library services launched by Distributed Bio, Inc. (US), a global leader in computational optimization of fully human monoclonal antibody libraries.  

Key Companies in the Antibody Drug Discovery Market includes.

• Charles River Laboratories (US)


• Biocytogen Pharmaceuticals Co., Ltd (China)


• Sartorius AG (Germany)


• Genscript Biotech Corporation (US)


• Creative Biolabs (US)


• Twist Bioscience (US)


• Fairjourney Biologics SA (Portugal)


• ProteoGenix (US)


• Absolute Antibody (UK)


• Sino Biological, Inc. (China)

Antibody Drug Discovery Industry Developments

• July 2021: PerkinElmer, Inc. (US) acquired BioLegend (US), a provider of antibodies and their reagents, for approximately USD 5.25 billion. BioLegend offers academic and biopharmaceutical customers quality-based reagents and antibodies.


• June 2021: GenScript Biotech (US) and Ligand Pharmaceuticals (US) entered into an agreement for global OmniAb licensing. This agreement enabled Genscript to rapidly expand its high-quality, fully human antibody discovery services to its customers worldwide.

Antibody Drug Discovery Market Segmentation

Antibody Drug Discovery Type Outlook

• Monoclonal Antibodies


• Polyclonal Antibodies


• Bispecific Antibodies


• Intracellular Antibodies

Antibody Drug Discovery Technique Outlook

• Hybridoma


• Phage Display


• Others

Antibody Drug Discovery Application Outlook

• Oncology


• Cardiology


• Infectious Diseases


• Autoimmune Diseases


• Others

Antibody Drug Discovery End User Outlook

• Pharmaceutical and Biotechnology Companies


• Contract Research Organizations


• Academic & Research Institutes

Antibody Drug Discovery Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America